142 related articles for article (PubMed ID: 19240767)
1. [Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy].
Benito-Martín A; Ucero AC; Santamaría B; Lorz C; Kretzler M; Rastaldi MP; Sánchez-Niño MD; Sanz A; Izquierdo MC; Ruiz Ortega M; Egido J; Ortiz A
Nefrologia; 2009; 29(1):13-9. PubMed ID: 19240767
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in cell death in human diabetic nephropathy.
Sanchez-Niño MD; Benito-Martin A; Ortiz A
Kidney Int; 2010 Oct; 78(8):737-44. PubMed ID: 20703212
[TBL] [Abstract][Full Text] [Related]
3. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.
Fernández Fernández B; Elewa U; Sánchez-Niño MD; Rojas-Rivera JE; Martin-Cleary C; Egido J; Ortiz A
Minerva Med; 2012 Aug; 103(4):219-34. PubMed ID: 22805616
[TBL] [Abstract][Full Text] [Related]
4. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney.
Candido R
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):69-74. PubMed ID: 24247823
[TBL] [Abstract][Full Text] [Related]
5. The role of inflammatory cytokines in diabetic nephropathy.
Navarro-González JF; Mora-Fernández C
J Am Soc Nephrol; 2008 Mar; 19(3):433-42. PubMed ID: 18256353
[TBL] [Abstract][Full Text] [Related]
6. The MIF receptor CD74 in diabetic podocyte injury.
Sanchez-Niño MD; Sanz AB; Ihalmo P; Lassila M; Holthofer H; Mezzano S; Aros C; Groop PH; Saleem MA; Mathieson PW; Langham R; Kretzler M; Nair V; Lemley KV; Nelson RG; Mervaala E; Mattinzoli D; Rastaldi MP; Ruiz-Ortega M; Martin-Ventura JL; Egido J; Ortiz A
J Am Soc Nephrol; 2009 Feb; 20(2):353-62. PubMed ID: 18842989
[TBL] [Abstract][Full Text] [Related]
7. The death ligand TRAIL in diabetic nephropathy.
Lorz C; Benito-Martín A; Boucherot A; Ucero AC; Rastaldi MP; Henger A; Armelloni S; Santamaría B; Berthier CC; Kretzler M; Egido J; Ortiz A
J Am Soc Nephrol; 2008 May; 19(5):904-14. PubMed ID: 18287563
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic perspectives for the role of inflammation in diabetic nephropathy.
Rivero A; Mora C; Muros M; García J; Herrera H; Navarro-González JF
Clin Sci (Lond); 2009 Mar; 116(6):479-92. PubMed ID: 19200057
[TBL] [Abstract][Full Text] [Related]
9. Transcription factors in the pathogenesis of diabetic nephropathy.
Sanchez AP; Sharma K
Expert Rev Mol Med; 2009 Apr; 11():e13. PubMed ID: 19397838
[TBL] [Abstract][Full Text] [Related]
10. [Effect of Astragalus mongholicus on renal gene expression profile in mice with diabetic nephropathy].
Hong XP; Zhang XZ; He XL; Huang XZ; Chen HR; Wang YZ
Zhongguo Zhong Yao Za Zhi; 2008 Mar; 33(6):676-80. PubMed ID: 18590199
[TBL] [Abstract][Full Text] [Related]
11. Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
Gong D; Chen X; Middleditch M; Huang L; Vazhoor Amarsingh G; Reddy S; Lu J; Zhang S; Ruggiero K; Phillips AR; Cooper GJ
Proteomics; 2009 Sep; 9(18):4309-20. PubMed ID: 19634143
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT re-expression.
Mirandola P; Gobbi G; Sponzilli I; Malinverno C; Cavazzoni A; Alfieri R; Petronini PG; Vitale M
J Cell Physiol; 2009 Aug; 220(2):492-8. PubMed ID: 19418484
[TBL] [Abstract][Full Text] [Related]
13. TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- mice.
Cartland SP; Erlich JH; Kavurma MM
PLoS One; 2014; 9(3):e92952. PubMed ID: 24667560
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of diabetic nephropathy.
Dronavalli S; Duka I; Bakris GL
Nat Clin Pract Endocrinol Metab; 2008 Aug; 4(8):444-52. PubMed ID: 18607402
[TBL] [Abstract][Full Text] [Related]
15. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy.
Navarro-González JF; Jarque A; Muros M; Mora C; García J
Cytokine Growth Factor Rev; 2009 Apr; 20(2):165-73. PubMed ID: 19251467
[TBL] [Abstract][Full Text] [Related]
17. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats.
Yeh CH; Chang CK; Cheng MF; Lin HJ; Cheng JT
Horm Metab Res; 2009 Aug; 41(8):605-11. PubMed ID: 19440953
[TBL] [Abstract][Full Text] [Related]
18. Genetics of diabetic nephropathy: lessons from mice.
Breyer MD; Tchekneva E; Qi Z; Takahashi T; Fogo AB; Zhao HJ; Harris RC
Semin Nephrol; 2007 Mar; 27(2):237-47. PubMed ID: 17418691
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the podocyte proteome in response to high glucose concentrations.
Schordan S; Schordan E; Endlich N; Lindenmeyer MT; Meyer-Schwesinger C; Meyer TN; Giebel J; Cohen CD; Endlich K; Maurer MH
Proteomics; 2009 Oct; 9(19):4519-28. PubMed ID: 19688724
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy.
Zhang Y; Zhang Q
Biochem Biophys Res Commun; 2009 May; 383(1):1-3. PubMed ID: 19303394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
